Compare BioNano Genomics Inc (BNGO) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Delta Air Lines, Inc. — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Delta Air Lines, Inc. trades at $85.65 (market cap $56.23B). The key difference: Delta Air Lines, Inc. is far larger — about 4259.8× BioNano Genomics Inc's market cap, and Delta Air Lines, Inc. pays a 0.91% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | DAL | |
|---|---|---|
Market Cap | $13.20M | $56.23B |
Sector | Health | Industrials |
52-Week High | $4.92 | $93.66 |
52-Week Low | $1.09 | $51.15 |
Enterprise Value | $15.81M | $71.55B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Delta Air Lines (DAL) trades at $86.19, down 1.37% on the day, with a bullish technical outlook supported by strong earnings beats and positive analyst sentiment. The stock shows solid fundamentals with a P/E of 14.29 and net income margin of 5.78%, while recent news highlights premium demand resilience and AI-driven customer satisfaction improvements. Cash flow trends have strengthened, with net cash flow turning positive in 2025 at $1.08 billion.
The outlook remains favorable with an 81.82% analyst buy rating and a $108.27 consensus price target implying 26% upside. Key risks include fuel cost volatility and competitive pressures, but strong institutional support and consistent earnings performance underpin potential for continued growth amid stable travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
